All Immunology articles
-
NewsCan this biotech innovation halt the destructive march of a cereal killer?
Researchers explored a recently discovered class of plant defence receptors, showing at molecular level how they function to limit blast pathogen attacks and how they might be bioengineered to introduce broader more durable immunity into wheat, barley, and rice.
-
NewsResearchers use computational design to engineer immune cells to fight cancer and viruses
Researchers have used advanced computational design methods to enhance the ability of genetically engineered immune cells to recognize and attack cancer and viral targets.
-
NewsTarget identified in treatment of neuroHIV
NeuroHIV occurs when HIV infection affects the function and structural integrity of the brain and, to some extent, the spinal cord and peripheral nervous system. New research has identified a brain protein driving this damage, pointing toward a possible treatment.
-
NewsGut microbiome development may help predict type 1 diabetes in children at high risk
A new prospective study found that children at high genetic risk of type 1 diabetes whose gut microbiome development plateaued early had about three times the risk of developing the disease compared with children whose microbiomes continued to mature.
-
NewsHow a single viral protein hijacks immune cells to supercharge COVID-19 infection
A new discovery reveals how a SARS-CoV-2 protein reprograms immune cells to accelerate viral spread—and points to a new strategy for therapeutic intervention.
-
NewsBoosted BCG vaccine strategy significantly reduces tuberculosis relapse
A new study reveals that combining an immunotherapy with the traditional Bacille Calmette-Guérin (BCG) vaccine drastically lowers the risk of TB relapse in preclinical models.
-
NewsA tiny bacterium with a huge impact
Researchers have discovered that gut bacteria and the compounds they produce trigger biological processes that the human body on its own can only activate with difficulty. They help suppress inflammation and may also have beneficial effects on fatty liver disease.
-
NewsVaccination: why don’t we all experience the same side effects?
Researchers have found that, even before vaccination, some people’s innate immune systems are more reactive than others, showing a heightened response to interferons. The stronger this response, the more likely individuals are to experience these transient symptoms.
-
NewsNew sepsis guidelines seek to reduce infection’s deadly toll
Experts have developed important new guidelines to improve care for patients who develop sepsis, a dangerous full-body infection that kills at least 350,000 Americans every year.
-
NewsLong-acting antibodies may work with the immune system to control HIV and help reduce the reservoir
Results from a clinical trial have offered a new HIV strategy, suggesting that just one or two doses of broadly neutralizing antibodies (bNAbs) can suppress the virus long-term, keeping it at undetectable levels for months and even years.
-
NewsResearchers discover how Epstein-Barr Virus triggers multiple sclerosis attacks
In a study of blood samples from more than 100 participants with MS, researchers detected increased EBV lytic activity in immune cells up to three months before MS relapse and discovered that these cells also showed elevated expression of genes linked to MS risk.
-
NewsBeyond the gut: Necrotizing enterocolitis drives neurodevelopmental impairment through gut-derived inflammation
A severe gut disease in premature infants, known as necrotizing enterocolitis (NEC), does far more than damage the intestines—it fundamentally alters brain development, leaving up to 40% of survivors with lasting cognitive, motor, and behavioral impairments.
-
NewsCan probiotics help T cells fight solid tumors more effectively?
Transferred T cells often have difficulty reaching tumors and overcoming the strongly immunosuppressive environment surrounding cancer cells. Researchers have combined therapeutic T cells with engineered probiotics, physically attaching the bacteria to the surface of T cells to create a hybrid system called T-FOLactis.
-
NewsFecal microbiota transplantation may improve immunotherapy-related colitis
Targeting the gut microbiome with fecal microbiota transplantation may help cancer patients with immunotherapy-related colitis avoid the need for steroids and other immune-suppressing treatments, according to researchers.
-
NewsImmunization to prevent RSV in infants reduced ICU admissions by 97 per cent
A new immunization, offered free to all infants through universal programs in two Canadian provinces, provided strong protection against respiratory syncytial virus, commonly referred to as RSV, sharply reducing hospitalizations and intensive care unit (ICU) admissions in infants.
-
NewsThe usefulness of labelled white blood cells in diagnosing necrotizing external otitis
Using radiopharmaceutical technology, researchers can reliably and conveniently diagnose and monitor necrotizing external otitis, a rare disease of the skull base.
-
NewsStudy uncovers how mRNA vaccination may broaden flu antibody responses
A new study finds that mRNA vaccination sustained influenza-specific germinal-center activity for up to six months in some participants.
-
NewsWhen antiviral defense and autoimmunity collide: New insights into lupus genetics
Researchers have found that a common lupus-associated genetic variant may strengthen antiviral immune responses while increasing the risk of autoimmunity.
-
NewsThe Wistar Institute wins $15M+ NIH investment to advance HIV cure research strategies
The Wistar Institute has announced the National Institutes of Health (NIH) has awarded two major grants totaling more than $15M to Luis J. Montaner, D.V.M., D.Phil., director of Wistar’s HIV Cure and Viral Diseases Center.
-
NewsResearchers discover highly potent compound that blocks Ebola virus entry
A research team has discovered a highly potent small molecule that blocks Ebola virus entry by stabilizing the virus’s entry protein and provides strong protection when given orally in a preclinical model. It is more than 100 times more potent than previously reported Ebola entry inhibitors.